{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:38Z","timestamp":1790742038930,"version":"4.1.0"},"reference-count":58,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,20]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors (BTKis) and cell therapy have successfully been used to treat mantle cell lymphoma (MCL). However, therapy resistance inevitably emerges. Cancer cells can progressively develop stable resistance by traversing through a transient drug-tolerant persister (DTP) state. The mechanisms enabling DTP cells to reversibly adapt to therapies and evolve to acquire heterogeneity remain poorly understood, and characterizing DTP cells in MCL continues to pose a challenge for clinic translation. Here, using pirtobrutinib, a recently US Food and Drug Administration\u2013approved noncovalent BTKi, we identified pirtobrutinib-tolerant persister cells exhibiting morphological variability by presenting a unique population of enlarged cells (giant cells) with reversible fate transitions. During treatment, giant cells enter a nonproliferative, dedifferentiated state, addicted to an activated cytosolic tricarboxylic acid (TCA) cycle coupled with the malate-aspartate shuttle to engage in biosynthesis. Upon drug removal, the TCA cycle shifts to oxidative catabolism, promoting giant cells to differentiate into regular-sized cells. Throughout the transition, acetyl coenzyme A modulates cell fate by fine-tuning stemness. Our biphasic model demonstrates that the metabolic switch governs the phenotypic plasticity of DTP cells in MCL, resulting in a dynamic presence of DTP cells across various developmental states in response to systemic therapies. Targeting giant cells before their differentiation offers a promising strategy to overcoming therapy resistance in MCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2024026919","type":"journal-article","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T18:17:48Z","timestamp":1753294668000},"page":"2544-2560","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["TCA cycle mode switch determines the fate of pirtobrutinib-tolerant persister cells in mantle cell lymphoma"],"prefix":"10.1182","volume":"146","author":[{"given":"Wei","family":"Wang","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-5013","authenticated-orcid":false,"given":"Lei","family":"Nie","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7813-1292","authenticated-orcid":false,"given":"Heng-Huan","family":"Lee","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Fei","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tan","sequence":"additional","affiliation":[{"name":"2Department of Bioinformatics and Computational Biology, Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0385-7774","authenticated-orcid":false,"given":"Philip L.","family":"Lorenzi","sequence":"additional","affiliation":[{"name":"2Department of Bioinformatics and Computational Biology, Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Nai","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yao","sequence":"additional","affiliation":[{"name":"3Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph Mitchell","family":"McIntosh","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Tai","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-4438","authenticated-orcid":false,"given":"Vivian C.","family":"Jiang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanny","family":"Vargas","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianci","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6857-0523","authenticated-orcid":false,"given":"Shaoying","family":"Li","sequence":"additional","affiliation":[{"name":"4Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Santos","sequence":"additional","affiliation":[{"name":"5Division of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvi","family":"Thirumurthi","sequence":"additional","affiliation":[{"name":"6Division of Internal Medicine, Department of Gastroenterology Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8000-5754","authenticated-orcid":false,"given":"Erin Heather","family":"Seeley","sequence":"additional","affiliation":[{"name":"7Department of Chemistry, Mass Spectrometry Imaging Facility at The University of Texas at Austin, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas Mikolaj","family":"Simon","sequence":"additional","affiliation":[{"name":"8Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Therapeutic Innovation Center at Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9524-3990","authenticated-orcid":false,"given":"Christopher","family":"Flowers","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6822-7880","authenticated-orcid":false,"given":"Chi Young","family":"Ok","sequence":"additional","affiliation":[{"name":"4Division of Pathology and Laboratory Medicine, Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"9Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7467","key":"2025112011215345200_bib1","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature12624","article-title":"Tumour heterogeneity and cancer cell plasticity","volume":"501","author":"Meacham","year":"2013","journal-title":"Nature"},{"issue":"5","key":"2025112011215345200_bib2","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.hoc.2020.06.001","article-title":"What is responsible for heterogeneity in mantle cell lymphoma biology and outcomes?","volume":"34","author":"Witzig","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"13","key":"2025112011215345200_bib3","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","article-title":"Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Hill","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2025112011215345200_bib4","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3324\/haematol.2009.013318","article-title":"Lymphoma stem cells: enough evidence to support their existence?","volume":"95","author":"Martinez-Climent","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2025112011215345200_bib5","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2025112011215345200_bib6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"issue":"11","key":"2025112011215345200_bib7","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025112011215345200_bib8","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cell.2020.11.018","article-title":"Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy","volume":"184","author":"Rehman","year":"2021","journal-title":"Cell"},{"issue":"8022","key":"2025112011215345200_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Fran\u00e7a","year":"2024","journal-title":"Nature"},{"issue":"12","key":"2025112011215345200_bib10","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1016\/j.cell.2024.04.032","article-title":"A developmental constraint model of cancer cell states and tumor heterogeneity","volume":"187","author":"Patel","year":"2024","journal-title":"Cell"},{"issue":"10","key":"2025112011215345200_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2025112011215345200_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.cell.2008.03.028","article-title":"Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency","volume":"133","author":"Hanna","year":"2008","journal-title":"Cell"},{"issue":"4","key":"2025112011215345200_bib13","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"issue":"7901","key":"2025112011215345200_bib14","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-022-04475-w","article-title":"A non-canonical tricarboxylic acid cycle underlies cellular identity","volume":"603","author":"Arnold","year":"2022","journal-title":"Nature"},{"issue":"3","key":"2025112011215345200_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025112011215345200_bib16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"491","key":"2025112011215345200_bib17","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025112011215345200_bib18","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"10277","key":"2025112011215345200_bib19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2025112011215345200_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"2025112011215345200_bib21","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid mantle cell lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"2025112011215345200_bib22","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","article-title":"Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2025112011215345200_bib23","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2025112011215345200_bib24","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.2022.282031","article-title":"Pirtobrutinib and venetoclax combination overcomes resistance to targeted and chimeric antigen receptor T-cell therapy in aggressive mantle cell lymphoma","volume":"108","author":"Liu","year":"2023","journal-title":"Haematologica"},{"issue":"488","key":"2025112011215345200_bib25","doi-asserted-by":"crossref","first-page":"eaav0936","DOI":"10.1126\/scitranslmed.aav0936","article-title":"Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state","volume":"11","author":"Echeverria","year":"2019","journal-title":"Sci Transl Med"},{"issue":"29","key":"2025112011215345200_bib26","doi-asserted-by":"crossref","first-page":"eadf7195","DOI":"10.1126\/sciadv.adf7195","article-title":"Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer","volume":"9","author":"Zhang","year":"2023","journal-title":"Sci Adv"},{"issue":"1","key":"2025112011215345200_bib27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/onc.2013.96","article-title":"Generation of cancer stem-like cells through the formation of polyploid giant cancer cells","volume":"33","author":"Zhang","year":"2014","journal-title":"Oncogene"},{"issue":"6682","key":"2025112011215345200_bib28","doi-asserted-by":"crossref","first-page":"eadi5798","DOI":"10.1126\/science.adi5798","article-title":"Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127","volume":"383","author":"Montoya","year":"2024","journal-title":"Science"},{"issue":"8","key":"2025112011215345200_bib29","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical gene-set enrichment tool for animals and plants","volume":"36","author":"Ge","year":"2020","journal-title":"Bioinformatics"},{"issue":"13","key":"2025112011215345200_bib30","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"5","key":"2025112011215345200_bib31","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1182\/blood-2008-02-078071","article-title":"B lymphocytes: how they develop and function","volume":"112","author":"LeBien","year":"2008","journal-title":"Blood"},{"issue":"D1","key":"2025112011215345200_bib32","doi-asserted-by":"crossref","first-page":"D870","DOI":"10.1093\/nar\/gkac947","article-title":"CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data","volume":"51","author":"Hu","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2025112011215345200_bib33","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41467-019-10100-8","article-title":"Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease","volume":"10","author":"Prakash","year":"2019","journal-title":"Nat Commun"},{"issue":"20","key":"2025112011215345200_bib34","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1101\/gad.1228804","article-title":"A dynamic transcriptional network communicates growth potential to ribosome synthesis and critical cell size","volume":"18","author":"Jorgensen","year":"2004","journal-title":"Genes Dev"},{"issue":"20","key":"2025112011215345200_bib35","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1101\/gad.1256704","article-title":"What better measure than ribosome synthesis?","volume":"18","author":"Rudra","year":"2004","journal-title":"Genes Dev"},{"issue":"6236","key":"2025112011215345200_bib36","doi-asserted-by":"crossref","first-page":"1245075","DOI":"10.1126\/science.1245075","article-title":"Cell biology. On being the right (cell) size","volume":"348","author":"Ginzberg","year":"2015","journal-title":"Science"},{"issue":"7","key":"2025112011215345200_bib37","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4161\/cc.6.7.4049","article-title":"Is cell size important?","volume":"6","author":"Baserga","year":"2007","journal-title":"Cell Cycle"},{"key":"2025112011215345200_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gde.2015.07.006","article-title":"New tricks for an old dog: ribosome biogenesis contributes to stem cell homeostasis","volume":"34","author":"Brombin","year":"2015","journal-title":"Curr Opin Genet Dev"},{"issue":"6476","key":"2025112011215345200_bib39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.aax0249","article-title":"Single-cell transcriptional diversity is a hallmark of developmental potential","volume":"367","author":"Gulati","year":"2020","journal-title":"Science"},{"key":"2025112011215345200_bib40","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"issue":"11","key":"2025112011215345200_bib41","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/iub.2367","article-title":"The malate-aspartate shuttle (Borst cycle): how it started and developed into a major metabolic pathway","volume":"72","author":"Borst","year":"2020","journal-title":"IUBMB Life"},{"issue":"11","key":"2025112011215345200_bib42","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1016\/j.cmet.2024.09.014","article-title":"Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2","volume":"36","author":"Lv","year":"2024","journal-title":"Cell Metab"},{"issue":"5930","key":"2025112011215345200_bib43","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1126\/science.1164097","article-title":"ATP-citrate lyase links cellular metabolism to histone acetylation","volume":"324","author":"Wellen","year":"2009","journal-title":"Science"},{"issue":"3","key":"2025112011215345200_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","article-title":"Acetyl-CoA metabolism in cancer","volume":"23","author":"Guertin","year":"2023","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"2025112011215345200_bib45","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nbt1009-917","article-title":"Introducing the acetylome","volume":"27","author":"Smith","year":"2009","journal-title":"Nat Biotechnol"},{"issue":"8","key":"2025112011215345200_bib46","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cac2.12332","article-title":"Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells","volume":"42","author":"Han","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"10","key":"2025112011215345200_bib47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/nm.4409","article-title":"Cancer stem cells revisited","volume":"23","author":"Batlle","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"2025112011215345200_bib48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.tcb.2022.08.001","article-title":"Mitochondria in cancer: clean windmills or stressed tinkerers?","volume":"33","author":"Altieri","year":"2023","journal-title":"Trends Cell Biol"},{"issue":"7","key":"2025112011215345200_bib49","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.cmet.2024.05.014","article-title":"Electron transport chain inhibition increases cellular dependence on purine transport and salvage","volume":"36","author":"Wu","year":"2024","journal-title":"Cell Metab"},{"issue":"23","key":"2025112011215345200_bib50","doi-asserted-by":"crossref","first-page":"e111239","DOI":"10.15252\/embj.2022111239","article-title":"Hypoxia promotes osteogenesis by facilitating acetyl-CoA-mediated mitochondrial-nuclear communication","volume":"41","author":"Pouikli","year":"2022","journal-title":"EMBO J"},{"issue":"9","key":"2025112011215345200_bib51","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1111\/cns.13892","article-title":"Hypoxia-induced polypoid giant cancer cells in glioma promote the transformation of tumor-associated macrophages to a tumor-supportive phenotype","volume":"28","author":"Liu","year":"2022","journal-title":"CNS Neurosci Ther"},{"issue":"7","key":"2025112011215345200_bib52","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1158\/2159-8290.CD-19-0015","article-title":"Cellular plasticity in cancer","volume":"9","author":"Yuan","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"2025112011215345200_bib53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/anie.196505581","article-title":"Anaplerotic sequences in microbial metabolism","volume":"4","author":"Kornberg","year":"1965","journal-title":"Angew Chem Int Ed Engl"},{"issue":"3","key":"2025112011215345200_bib54","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and implications of metabolic heterogeneity in cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab"},{"issue":"3","key":"2025112011215345200_bib55","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2015.07.016","article-title":"An essential role of the mitochondrial electron transport chain in cell proliferation is to enable aspartate synthesis","volume":"162","author":"Birsoy","year":"2015","journal-title":"Cell"},{"issue":"3","key":"2025112011215345200_bib56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"issue":"8","key":"2025112011215345200_bib57","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.15252\/embj.201591041","article-title":"SIRT3-dependent GOT2 acetylation status affects the malate-aspartate NADH shuttle activity and pancreatic tumor growth","volume":"34","author":"Yang","year":"2015","journal-title":"EMBO J"},{"issue":"5942","key":"2025112011215345200_bib58","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1126\/science.1175371","article-title":"Lysine acetylation targets protein complexes and co-regulates major cellular functions","volume":"325","author":"Choudhary","year":"2009","journal-title":"Science"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2544\/2421345\/blood_bld-2024-026919-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/21\/2544\/2421345\/blood_bld-2024-026919-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:22:06Z","timestamp":1763655726000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/21\/2544\/546313\/TCA-cycle-mode-switch-determines-the-fate-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":58,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026919","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,20]]},"published":{"date-parts":[[2025,11,20]]}}}